{"success":true,"data":{"pressRelease":{"id":"25749","rtpr_id":"nGNE3MKTYv","ticker":"NOVN","exchange":"","all_tickers":["NOVN"],"title":"Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities","author":"Globe Newswire","published_at":"2026-05-07T13:00:00.154Z","article_body":"* US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent\nHagenbuch, Novartis leadership mark expansion of company’s coast-to-coast\nRLT manufacturing network – the largest in the US\n* Expanded infrastructure brings highly personalized cancer therapies closer\nto patients across the southern US\n* Denton groundbreaking is latest milestone in Novartis’ $23 billion\ninvestment in US research and manufacturing\nBasel, May 7, 2026 – Novartis, a leading global innovative medicines\ncompany, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT)\nmanufacturing site in Denton, Texas, the latest milestone in its broader\n$23 billion investment in US manufacturing and research. The start of\nconstruction on the company’s first Texas‑based manufacturing facility\nbrings US RLT production closer to patients across the southern US, becoming\nthe fifth RLT site nationwide.\n\n“Radioligand therapy is transforming how we treat cancer, and expanded\nmanufacturing is essential to delivering these therapies at scale,” said Vas\nNarasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens\nour US supply chain and helps ensure patients can receive these highly\npersonalized treatments when and where they need them.”\n\nThis expansion reinforces Novartis’ leadership as the first company to\ndeliver RLT at scale, building the network capacity needed as these therapies\nextend into earlier stages of treatment and a broader range of cancers.\nAnnounced earlier this year, the site is expected to become operational in\n2028 and create new US-based Novartis jobs in bioengineering, advanced\nmanufacturing, quality, and operations, supporting economic growth in Denton\nand surrounding communities. \n\nUS Under Secretary of Commerce for Industry and Security Jeffrey Kessler,\nSwiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch,\nTexas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth\njoined Novartis leadership, employees, and community partners to celebrate the\nstart of construction. \n\n“I’m pleased to welcome Novartis to Denton as their newest manufacturing\nlocation for their cancer therapies,” said Texas State Senator Brent\nHagenbuch. “Their decision establishes a strong partnership and reflects the\nunique opportunity Denton provides to a well-educated workforce, and the\nunique access the new plant location will provide to the vibrant North Texas\neconomy and rapidly growing state population.”\n\nThe Texas facility bolsters the Novartis coast-to-coast RLT manufacturing\nnetwork (https://www.novartis.com/us-en/about/investing-americas-health), with\nexisting US sites in New Jersey, Indiana and California, and a new site being\nadded in Florida. The Denton site adds to the largest US RLT manufacturing\nnetwork and further builds on the company’s longstanding track record of\nenabling >99% of doses to be administered on the planned day of treatment.\nEach dose of RLT is custom-made and requires precise coordination, making\nmanufacturing reliability and proximity to treatment centers critical to\ndelivering treatment as planned.\n\nIn April 2025, Novartis committed $23 billion over five years to grow its US\nresearch and manufacturing footprint. Seven new and three expanded facilities\nacross the country are already under construction – part of the company’s\nbroader effort to manufacture all key medicines for US patients in the US,\nsupporting supply resilience and dependable delivery of medicines. The Denton\ngroundbreaking builds on rapid progress across Novartis’ US investment plan.\n* May 2026: Breaking ground on a new RLT manufacturing facility in Denton,\nTexas, to produce cancer treatments, expanding the company’s coast-to-coast\nRLT network to five sites (site location previously announced in February\n2026)\n* April 2026: Announced a new facility in Morrisville, North Carolina, focused\non active pharmaceutical ingredient manufacturing for solid dosage\ntablets, capsules and RNA therapeutics across oncology, immunology, and\ncardiovascular, renal and metabolic diseases\n* February 2026: Broke ground on a new biomedical research center in San\nDiego, California, expanding its US research presence alongside Cambridge,\nMassachusetts, and supporting discovery across disease areas including\nneuroscience and oncology\n* January 2026: Announced a new RLT manufacturing facility for cancer\ntreatments in Winter Park, Florida, the first in the southeastern US\n* December 2025: Broke ground on a flagship manufacturing hub in North\nCarolina, adding solid dosage tablet and capsule and biologics production and\nsterile packaging for treatments across oncology, immunology, neuroscience,\nand cardiovascular, renal and metabolic diseases\n* November 2025: Opened a new RLT manufacturing facility for cancer treatments\nin Carlsbad, California – the first such site in the region serving the\nwestern US, Alaska, and Hawaii\n* Ongoing: Expansions of existing RLT facilities in Indianapolis, Indiana, and\nMillburn, New Jersey, supporting current and future demand for these cancer\ntreatments\nNovartis and radioligand therapy (RLT)\nNovartis is reimagining cancer care with RLT for patients with advanced\ncancers. By harnessing the power of targeted radiation and applying it to\nadvanced cancers, RLT is designed to deliver treatment directly to target\ncells anywhere in the body.  \n\nNovartis is actively investigating the application of RLTs across cancer types\nand settings, with one of the deepest and most advanced pipelines in the\nindustry, with trials in prostate cancer, breast, colon, lung, brain,\npancreatic and other cancers. Novartis has established global expertise, with\nspecialized supply chain and manufacturing capabilities across its network of\nRLT production sites around the world.\n\nDisclaimer\nThis press release contains forward-looking statements within the meaning of\nthe United States Private Securities Litigation Reform Act of 1995.\nForward-looking statements can generally be identified by words such as\n“potential,” “can,” “will,” “plan,” “may,” “could,”\n“would,” “expect,” “anticipate,” “look forward,” or similar\nexpressions, or by express or implied discussions regarding: potential new\nproducts; potential new indications for existing products; potential product\nlaunches or potential future revenues from any such products; results of\nongoing clinical trials; or potential future, pending or announced\ntransactions; potential future sales or earnings; or strategy, plans,\nexpectations or intentions, including discussions regarding our continued\ninvestment into new R&D capabilities and manufacturing. You should not place\nundue reliance on these statements. Such forward-looking statements are based\non the current beliefs and expectations of management regarding future events,\nand are subject to significant known and unknown risks and uncertainties.\nShould one or more of these risks or uncertainties materialize, or should\nunderlying assumptions prove incorrect, actual results may vary materially\nfrom those set forth in the forward-looking statements. There can be no\nguarantee that the investigational or approved products described in this\npress release will be submitted or approved for sale or for any additional\nindications or labeling in any market, or at any particular time. Neither can\nthere be any guarantee that such products will be commercially successful in\nthe future. Nor can there be any guarantee that the expected benefits from the\nplans and investments described in this press release will be achieved in the\nexpected timeframe, or at all. In particular, our expectations could be\naffected by, among other things, uncertainties concerning: global healthcare\ncost containment, including ongoing government, payer and general public\npricing and reimbursement pressures and requirements for increased pricing\ntransparency; the success of our key products, commercial priorities and\nstrategy; research and development of new products, including clinical trial\nresults and additional analysis of existing clinical data; our ability to\nobtain or maintain proprietary intellectual property protection, including the\nultimate extent of the impact on Novartis of the loss of patent protection and\nexclusivity on key products; our ability to realize the strategic benefits,\noperational efficiencies or opportunities expected from our external business\nopportunities; the development or adoption of new technologies, including\nartificial intelligence, and new business models; potential significant\nbreaches of information security or disruptions of our information technology\nsystems; actual or potential legal proceedings, including regulatory actions\nor delays or government regulation related to the products and pipeline\nproducts described in this press release; safety, quality, data integrity, or\nmanufacturing issues; major macroeconomic and geo- and socio-political\ndevelopments, including the impact of any potential tariffs on our products or\nthe impact of war in certain parts of the world; future global exchange rates;\nfuture demand for our products; and other risks and factors referred to in\nNovartis AG’s most recently filed Form 20-F and in subsequent reports filed\nwith, or furnished to, the US Securities and Exchange Commission. Novartis is\nproviding the information in this press release as of this date and does not\nundertake any obligation to update any forward-looking statements as a result\nof new information, future events or otherwise.\n\nAbout Novartis \nNovartis is an innovative medicines company. Every day, we work to reimagine\nmedicine to improve and extend people’s lives so that patients, healthcare\nprofessionals and societies are empowered in the face of serious disease. Our\nmedicines reach more than 300 million people worldwide.\n\nReimagine medicine with us: Visit us at https://www.novartis.com and connect\nwith us on LinkedIn (https://www.linkedin.com/company/novartis/), Facebook\n(https://www.facebook.com/novartis/), X/Twitter (https://twitter.com/Novartis)\nand Instagram\n(https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$).\n\n# # #\n\n Novartis Media Relations E-mail: media.relations@novartis.com                                                         \n Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE3MKTYv","title":"Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities","author":"Globe Newswire","ticker":"NOVN","created":"2026-05-07T13:00:00.154Z","tickers":["NOVN"],"exchange":"","article_body":"* US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent\nHagenbuch, Novartis leadership mark expansion of company’s coast-to-coast\nRLT manufacturing network – the largest in the US\n* Expanded infrastructure brings highly personalized cancer therapies closer\nto patients across the southern US\n* Denton groundbreaking is latest milestone in Novartis’ $23 billion\ninvestment in US research and manufacturing\nBasel, May 7, 2026 – Novartis, a leading global innovative medicines\ncompany, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT)\nmanufacturing site in Denton, Texas, the latest milestone in its broader\n$23 billion investment in US manufacturing and research. The start of\nconstruction on the company’s first Texas‑based manufacturing facility\nbrings US RLT production closer to patients across the southern US, becoming\nthe fifth RLT site nationwide.\n\n“Radioligand therapy is transforming how we treat cancer, and expanded\nmanufacturing is essential to delivering these therapies at scale,” said Vas\nNarasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens\nour US supply chain and helps ensure patients can receive these highly\npersonalized treatments when and where they need them.”\n\nThis expansion reinforces Novartis’ leadership as the first company to\ndeliver RLT at scale, building the network capacity needed as these therapies\nextend into earlier stages of treatment and a broader range of cancers.\nAnnounced earlier this year, the site is expected to become operational in\n2028 and create new US-based Novartis jobs in bioengineering, advanced\nmanufacturing, quality, and operations, supporting economic growth in Denton\nand surrounding communities. \n\nUS Under Secretary of Commerce for Industry and Security Jeffrey Kessler,\nSwiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch,\nTexas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth\njoined Novartis leadership, employees, and community partners to celebrate the\nstart of construction. \n\n“I’m pleased to welcome Novartis to Denton as their newest manufacturing\nlocation for their cancer therapies,” said Texas State Senator Brent\nHagenbuch. “Their decision establishes a strong partnership and reflects the\nunique opportunity Denton provides to a well-educated workforce, and the\nunique access the new plant location will provide to the vibrant North Texas\neconomy and rapidly growing state population.”\n\nThe Texas facility bolsters the Novartis coast-to-coast RLT manufacturing\nnetwork (https://www.novartis.com/us-en/about/investing-americas-health), with\nexisting US sites in New Jersey, Indiana and California, and a new site being\nadded in Florida. The Denton site adds to the largest US RLT manufacturing\nnetwork and further builds on the company’s longstanding track record of\nenabling >99% of doses to be administered on the planned day of treatment.\nEach dose of RLT is custom-made and requires precise coordination, making\nmanufacturing reliability and proximity to treatment centers critical to\ndelivering treatment as planned.\n\nIn April 2025, Novartis committed $23 billion over five years to grow its US\nresearch and manufacturing footprint. Seven new and three expanded facilities\nacross the country are already under construction – part of the company’s\nbroader effort to manufacture all key medicines for US patients in the US,\nsupporting supply resilience and dependable delivery of medicines. The Denton\ngroundbreaking builds on rapid progress across Novartis’ US investment plan.\n* May 2026: Breaking ground on a new RLT manufacturing facility in Denton,\nTexas, to produce cancer treatments, expanding the company’s coast-to-coast\nRLT network to five sites (site location previously announced in February\n2026)\n* April 2026: Announced a new facility in Morrisville, North Carolina, focused\non active pharmaceutical ingredient manufacturing for solid dosage\ntablets, capsules and RNA therapeutics across oncology, immunology, and\ncardiovascular, renal and metabolic diseases\n* February 2026: Broke ground on a new biomedical research center in San\nDiego, California, expanding its US research presence alongside Cambridge,\nMassachusetts, and supporting discovery across disease areas including\nneuroscience and oncology\n* January 2026: Announced a new RLT manufacturing facility for cancer\ntreatments in Winter Park, Florida, the first in the southeastern US\n* December 2025: Broke ground on a flagship manufacturing hub in North\nCarolina, adding solid dosage tablet and capsule and biologics production and\nsterile packaging for treatments across oncology, immunology, neuroscience,\nand cardiovascular, renal and metabolic diseases\n* November 2025: Opened a new RLT manufacturing facility for cancer treatments\nin Carlsbad, California – the first such site in the region serving the\nwestern US, Alaska, and Hawaii\n* Ongoing: Expansions of existing RLT facilities in Indianapolis, Indiana, and\nMillburn, New Jersey, supporting current and future demand for these cancer\ntreatments\nNovartis and radioligand therapy (RLT)\nNovartis is reimagining cancer care with RLT for patients with advanced\ncancers. By harnessing the power of targeted radiation and applying it to\nadvanced cancers, RLT is designed to deliver treatment directly to target\ncells anywhere in the body.  \n\nNovartis is actively investigating the application of RLTs across cancer types\nand settings, with one of the deepest and most advanced pipelines in the\nindustry, with trials in prostate cancer, breast, colon, lung, brain,\npancreatic and other cancers. Novartis has established global expertise, with\nspecialized supply chain and manufacturing capabilities across its network of\nRLT production sites around the world.\n\nDisclaimer\nThis press release contains forward-looking statements within the meaning of\nthe United States Private Securities Litigation Reform Act of 1995.\nForward-looking statements can generally be identified by words such as\n“potential,” “can,” “will,” “plan,” “may,” “could,”\n“would,” “expect,” “anticipate,” “look forward,” or similar\nexpressions, or by express or implied discussions regarding: potential new\nproducts; potential new indications for existing products; potential product\nlaunches or potential future revenues from any such products; results of\nongoing clinical trials; or potential future, pending or announced\ntransactions; potential future sales or earnings; or strategy, plans,\nexpectations or intentions, including discussions regarding our continued\ninvestment into new R&D capabilities and manufacturing. You should not place\nundue reliance on these statements. Such forward-looking statements are based\non the current beliefs and expectations of management regarding future events,\nand are subject to significant known and unknown risks and uncertainties.\nShould one or more of these risks or uncertainties materialize, or should\nunderlying assumptions prove incorrect, actual results may vary materially\nfrom those set forth in the forward-looking statements. There can be no\nguarantee that the investigational or approved products described in this\npress release will be submitted or approved for sale or for any additional\nindications or labeling in any market, or at any particular time. Neither can\nthere be any guarantee that such products will be commercially successful in\nthe future. Nor can there be any guarantee that the expected benefits from the\nplans and investments described in this press release will be achieved in the\nexpected timeframe, or at all. In particular, our expectations could be\naffected by, among other things, uncertainties concerning: global healthcare\ncost containment, including ongoing government, payer and general public\npricing and reimbursement pressures and requirements for increased pricing\ntransparency; the success of our key products, commercial priorities and\nstrategy; research and development of new products, including clinical trial\nresults and additional analysis of existing clinical data; our ability to\nobtain or maintain proprietary intellectual property protection, including the\nultimate extent of the impact on Novartis of the loss of patent protection and\nexclusivity on key products; our ability to realize the strategic benefits,\noperational efficiencies or opportunities expected from our external business\nopportunities; the development or adoption of new technologies, including\nartificial intelligence, and new business models; potential significant\nbreaches of information security or disruptions of our information technology\nsystems; actual or potential legal proceedings, including regulatory actions\nor delays or government regulation related to the products and pipeline\nproducts described in this press release; safety, quality, data integrity, or\nmanufacturing issues; major macroeconomic and geo- and socio-political\ndevelopments, including the impact of any potential tariffs on our products or\nthe impact of war in certain parts of the world; future global exchange rates;\nfuture demand for our products; and other risks and factors referred to in\nNovartis AG’s most recently filed Form 20-F and in subsequent reports filed\nwith, or furnished to, the US Securities and Exchange Commission. Novartis is\nproviding the information in this press release as of this date and does not\nundertake any obligation to update any forward-looking statements as a result\nof new information, future events or otherwise.\n\nAbout Novartis \nNovartis is an innovative medicines company. Every day, we work to reimagine\nmedicine to improve and extend people’s lives so that patients, healthcare\nprofessionals and societies are empowered in the face of serious disease. Our\nmedicines reach more than 300 million people worldwide.\n\nReimagine medicine with us: Visit us at https://www.novartis.com and connect\nwith us on LinkedIn (https://www.linkedin.com/company/novartis/), Facebook\n(https://www.facebook.com/novartis/), X/Twitter (https://twitter.com/Novartis)\nand Instagram\n(https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$).\n\n# # #\n\n Novartis Media Relations E-mail: media.relations@novartis.com                                                         \n Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com"},"type":"article","timestamp":"2026-05-07T13:00:00.313565048Z","server_sent_at_ms":1778158800313},"received_at":"2026-05-07T13:00:00.553Z","source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290059/0/en/novartis-breaks-ground-on-denton-texas-radioligand-therapy-site-construction-now-underway-across-all-new-us-facilities.html"},"analysis":{"id":"20153","press_release_id":"25749","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Novartis broke ground on a 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, expanding its coast-to-coast US network to five sites.\n\nThe new facility, expected to become operational in 2028, is part of a broader $23 billion five-year investment strategy to grow US research and manufacturing footprints.\n\nThis expansion aims to strengthen the supply chain for personalized cancer therapies, bringing production closer to patients in the southern US.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Novartis advances RLT manufacturing footprint with Texas groundbreaking."},"keyFigures":{"customDimensions":{"operational_year":2028,"facility_area_sqft":46000,"total_us_investment":"$23 billion"}},"quotedText":"Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale","namedEntities":{"people":[{"name":"Vas Narasimhan","role":"CEO"},{"name":"Jeffrey Kessler","role":"US Under Secretary of Commerce for Industry and Security"},{"name":"Brent Hagenbuch","role":"Texas State Senator"},{"name":"Andy Hopper","role":"Texas State Representative"},{"name":"Gerard Hudspeth","role":"Denton Mayor"},{"name":"Ralf Heckner","role":"Swiss Ambassador to the US"}],"products":["Radioligand therapy (RLT)"],"companies":[{"name":"Novartis","ticker":"NOVN"}],"dollarAmounts":[{"amount":"$23 billion","context":"five-year investment in US research and manufacturing"}]},"materialImpact":{"score":3,"reasoning":"Start of construction on the 5th US RLT site supports a key growth driver and confirms progress on a significant $23B multi-year investment, though operational revenue impact is deferred until 2028."},"tickerRelevance":{"others":[],"primary":"NOVN"},"globalImportance":30,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"facility_expansion","sectorWeight":"pharma_rlt_strategic_priority"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Novartis broke ground on a 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, expanding its coast-to-coast US network to five sites.\n\nThe new facility, expected to become operational in 2028, is part of a broader $23 billion five-year investment strategy to grow US research and manufacturing footprints.\n\nThis expansion aims to strengthen the supply chain for personalized cancer therapies, bringing production closer to patients in the southern US.","key_figures":{"customDimensions":{"operational_year":2028,"facility_area_sqft":46000,"total_us_investment":"$23 billion"}},"named_entities":{"people":[{"name":"Vas Narasimhan","role":"CEO"},{"name":"Jeffrey Kessler","role":"US Under Secretary of Commerce for Industry and Security"},{"name":"Brent Hagenbuch","role":"Texas State Senator"},{"name":"Andy Hopper","role":"Texas State Representative"},{"name":"Gerard Hudspeth","role":"Denton Mayor"},{"name":"Ralf Heckner","role":"Swiss Ambassador to the US"}],"products":["Radioligand therapy (RLT)"],"companies":[{"name":"Novartis","ticker":"NOVN"}],"dollarAmounts":[{"amount":"$23 billion","context":"five-year investment in US research and manufacturing"}]},"model_name":"glm-4.7","prompt_hash":"sha256:f66160e0fe5301b2","schema_hash":"sha256:12363694422af5d9","created_at":"2026-05-07T22:46:02.392Z","global_importance":30,"audience_relevance":45,"importance_components":{"tickerTier":"large-cap","eventGravity":"facility_expansion","sectorWeight":"pharma_rlt_strategic_priority"}},"durationMs":71399,"modelName":"glm-4.7"}}